President-elect Joe Biden promised the American people that he’d get 100 million vaccine doses to the American people within his first 100 days in office.
Sponsored: Dems inflating COVID #s to RIG 2020 election
So far, not so good.
According to multiple reports, Biden upset at his coronavirus transition team and its failure to coordinate a prolonged effort of vaccinations. Hiccups with working staff, technology troubles, and insurance coverage complexities are just a few of the issues slowing down Biden from completing his first big campaign promise.
The global pandemic that has engulfed the greater part of the country for nearly a year is harder to control than Biden expected.
President Donald Trump took unprecedented criticism for his response to COVID-19. Now, Biden is finding out it’s not so easy.
To make matters worse, the FDA isn’t even backing the Biden plan.
Biden’s method interrupts the plan of attack that Trump had already implemented, the FDA says — which has been initiating a slower rollout of the vaccine to insure that those who received their first shot would receive their second one.
The Trump administration is, however, expected Tuesday to announce a strategy to immunize Americans at a quicker rate.
The 3 foods that GROW cancer [sponsored]
Nevertheless, the FDA had suggested that Biden stick with Trump’s plan, which is geared toward getting vaccines to health care officials, first responders, and those at fatal risk for the disease.
The reality for Biden remains that he may see his first failure in the White House sooner rather than later.
“President-elect Joe Biden has grown frustrated with the team in charge of plotting his coronavirus response, amid rising concerns that his administration will fall short of its promise of 100 million vaccinations in the first 100 days, according to people familiar with the conversations,” Politico wrote Monday.
“Biden’s aggravation is rooted in the rush to build the foundation for an extended inoculation effort, a complex undertaking that includes untangling all manner of bureaucratic obstacles — from staffing issues to technology problems and insurance coverage dilemmas — that the transition had expected to already be well underway.”
The Horn editorial team